2019 American Transplant Congress
A Novel Method for Ex Vivo Treg Expansion via Human iNKT Cell Activation
*Purpose: Tregs play a critical role in immune tolerance. If Tregs can be administered to patients suffering from immune disorders, most therapies employing existing immunosuppressants…2019 American Transplant Congress
Chimeric Allografts Induced by Stem Cell Mobilizing Agents in a Mouse Model of Kidney Transplantation: Role of CD133 Stem Cells
Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: It has been reported that a stem cell mobilizing therapy using a combination of AMD3100 and low dose FK506 (AF) enabled immunosuppressive-free long-term kidney…2019 American Transplant Congress
α -1,3-galactosyltransferase Knockout Porcine Tissue And Organ May Reduce The Risks Of Antibody Mediated Rejection Via Less Rhesus Igm Cross-reactivity.
Duke Transplant Center, Durham, NC
*Purpose: Previously, we observed that sera from rhesus macaques contained preformed antibodies against wild type (WT) swine splenocytes. In the context of xenotransplantation, preformed xenoantibodies…2019 American Transplant Congress
Recipient Myeloid Notch1 Disruption Shifts Neutrophil towards Anti-Inflammatory Phenotype and Protects Liver Grafts from Ischemia-Reperfusion Injury
*Purpose: Liver ischemia-reperfusion injury (IRI) represents a major risk factor of early graft dysfunction and predisposes to rejection crises in orthotopic liver transplantation (OLT). We…2019 American Transplant Congress
Bisphosphonates Effectively Improve the Long Term Renal Transplant Outcomes; A Single Center Retrospective Study
*Purpose: Kidney transplantation (KT) is a treatment of choice for patients with end-stage renal disease. Despite of remarkable improvement in short term graft survival, few…2019 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (nct03380962)
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Currently, there is growing interest in development of novel immune-modulatory drugs likely to improve allo-antibody reduction in transplantation. Clazakizumab (Vitaeris Inc.) is a humanized…2019 American Transplant Congress
Late Acute Rejection Increases Risk Of Graft Failure In Ldlt Recipients: Data From The A2all Cohort
University of California, San Francisco, San Francisco, CA
*Purpose: Late acute rejection (LAR) is defined as an initial episode of acute rejection occurring >6 months after transplantation. LAR in liver transplantation (LT) is…2019 American Transplant Congress
One Study: A Consortium Model of Clinical Trials Optimized for Comparing New Immune Therapies via Centralized Immune Monitoring
*Purpose: Immune regulatory cell subpopulations can potentially control immune responses to allow immunosuppression (IS) drug minimization. In the ONE Study, an EU FP7-funded research group…2019 American Transplant Congress
Prevention of Graft Ischemia-Reperfusion Injury in Ischemia-Free Liver Transplantation
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
*Purpose: Graft ischemia-reperfusion injury (IRI) is an inevitable event in organ transplantation, which often leads to a number of complications and even patient deaths. We…2019 American Transplant Congress
Does the Type of Pre-Heart Transplant Desensitization Therapy Affect 5-Year Post-Transplant Outcomes?
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: As many patients with severe heart disease require mechanical circulatory support (MCS), the number of sensitized patients developing circulating antibodies continues to rise. In…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 214
- Next Page »